Company Overview
vTv Therapeutics Inc. operates as a late-stage biopharmaceutical company dedicated to developing oral small molecule drug candidates designed to treat patients living with diabetes and other chronic diseases. The company functions within the Healthcare sector, specifically inside the Biotechnology industry, a landscape characterized by high research and development costs and significant regulatory hurdles before products reach the market. Currently, the organization employs 26 individuals and holds a total market capitalization of $150.63M. Given that the company reports no revenue data, the market cap serves as the primary indicator of its valuation, reflecting the speculative nature of pre-revenue or late-stage biotech firms where value is derived entirely from the potential future success of pipeline assets rather than current cash flows.
Financial Health
The company reports a net income of $-26,974,000 for the trailing twelve months, while EBITDA stands at $-32,792,000, indicating substantial operating losses typical of entities in the developmental phase of drug discovery. Since revenue is listed as N/A, the gap between zero revenue and significant negative net income reveals that the company's cost structure is entirely driven by expenses such as research, development, and administrative overhead without any offsetting sales income. Free cash flow is reported at $-14,697,750, which signifies that the company is currently burning through cash reserves to fund its operations and research initiatives rather than generating liquidity from commercial activities. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a mathematical necessity when revenue is zero that indicates the company has not yet achieved commercial profitability. Despite these deficits, the company holds $88.93M in cash against N/A debt levels, suggesting a balance sheet that is highly conservative and leveraged-free given the absence of recorded liabilities. The current ratio stands at 13.54, a figure that indicates an exceptionally strong short-term liquidity position with current assets significantly exceeding current liabilities. Furthermore, the Return on Equity is -78.9% and the Return on Assets is -32.0%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than profits, which is standard for late-stage biotechs but highlights the financial risk associated with the current stage of development.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of earnings, while the forward P/E is listed as -10.27, implying that the market is pricing the stock based on anticipated future losses or revenue rather than current profitability. The price-to-book ratio is 7.36, indicating that the market values the company at more than seven times its book value, a premium often seen in biotechnology firms where intangible assets like intellectual property and pipeline potential are not fully reflected on the balance sheet. The price-to-sales ratio is N/A because there is no revenue data, and the EV/EBITDA stands at -10.91, suggesting that traditional valuation multiples based on earnings are not applicable and that investors are relying on alternative metrics to assess the company's worth. The stock has a 52-week high of $44.00 and a 52-week low of $14.00, providing a range within which the current price fluctuates based on market sentiment regarding the company's clinical progress and regulatory milestones. With a beta of 0.43, the stock exhibits lower volatility relative to the broader market, moving less than half as much as the S&P 500 during typical market swings, which may offer a degree of stability for long-term holders despite the high-risk nature of the biotech sector.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, as the company has not yet generated commercial revenue to calculate year-over-year percentage changes. In the absence of positive earnings, the concept of a sustainable dividend payout ratio does not apply, as the company currently does not pay dividends to shareholders. Instead of distributing income, the company reinvests its available cash reserves, currently totaling $88.93M, directly into its research and development efforts to advance its lead drug candidate, cadisegliatin (TTP399). The overall growth and income profile is defined by a total reliance on capital markets or cash reserves to fuel expansion, with no current income generation or dividend yield available to investors.